Therefore, our results shed light on the role of SALL2 in ER regulation and identify a potential clinical biosignature that could be used for subgrouping breast cancer patients and identify those who might benefit from tamoxifen/DNMT inhibitor co‐therapy. This evidence concerns the gene DNMT1 and breast cancer.